These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 16826359

  • 21. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
    Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, Hasegawa T.
    Radiat Med; 2004; 22(4):205-11. PubMed ID: 15468939
    [Abstract] [Full Text] [Related]

  • 22. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
    Mason KA, Hunter NR, Raju U, Ariga H, Husain A, Valdecanas D, Neal R, Ang KK, Milas L.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):1181-9. PubMed ID: 15234054
    [Abstract] [Full Text] [Related]

  • 23. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P.
    Blood Cells Mol Dis; 2005 Jul 15; 34(2):181-5. PubMed ID: 15727903
    [Abstract] [Full Text] [Related]

  • 24. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 15; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 25. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
    Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M.
    Oral Oncol; 2004 Aug 15; 40(7):713-9. PubMed ID: 15172641
    [Abstract] [Full Text] [Related]

  • 26. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 27. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N.
    Differentiation; 2007 Nov 01; 75(9):843-52. PubMed ID: 17999742
    [Abstract] [Full Text] [Related]

  • 28. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):892-900. PubMed ID: 18245553
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Feb 01; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

  • 30. (E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts.
    Sun LQ, Li YX, Guillou L, Coucke PA.
    Cancer Res; 1998 Dec 01; 58(23):5411-7. PubMed ID: 9850073
    [Abstract] [Full Text] [Related]

  • 31. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E.
    Clin Cancer Res; 2007 Dec 01; 13(23):7155-65. PubMed ID: 18056196
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
    Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN.
    Cancer Res; 2002 Dec 15; 62(24):7291-7. PubMed ID: 12499272
    [Abstract] [Full Text] [Related]

  • 33. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
    Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD.
    Cancer Res; 2000 Sep 15; 60(18):5143-50. PubMed ID: 11016641
    [Abstract] [Full Text] [Related]

  • 34. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
    Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW.
    Cancer Res; 2002 Mar 15; 62(6):1702-6. PubMed ID: 11912143
    [Abstract] [Full Text] [Related]

  • 35. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 36. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
    Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD.
    Cancer Res; 2001 Jan 01; 61(1):39-44. PubMed ID: 11196192
    [Abstract] [Full Text] [Related]

  • 37. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, Lu B.
    Cancer Res; 2006 Dec 01; 66(23):11409-15. PubMed ID: 17145887
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
    Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):479-89. PubMed ID: 12451475
    [Abstract] [Full Text] [Related]

  • 39. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.
    Cancer Res; 2006 Sep 01; 66(17):8715-21. PubMed ID: 16951187
    [Abstract] [Full Text] [Related]

  • 40. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Sep 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.